KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer

Ann Oncol. 2018 Dec 1;29(12):2280-2282. doi: 10.1093/annonc/mdy484.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Biomarkers
  • Circulating Tumor DNA*
  • Humans
  • Mutation
  • Pancreatic Neoplasms*
  • Proto-Oncogene Proteins p21(ras) / genetics

Substances

  • Biomarkers
  • Circulating Tumor DNA
  • KRAS protein, human
  • Proto-Oncogene Proteins p21(ras)